EurekAlert!

β-catenin/TCF4 is required for DDX17-induced epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma

The diagram illustrates the key mechanisms of DDX17-induced hepatocellular carcinoma metastasis: DDX17 promotes nuclear translocation of β-catenin; in the nucleus, β-catenin forms a complex with TCF4, ...
Medscape

Endometrial Cancer Recurrence Linked to Beta-Catenin Levels

Women with early-stage endometrial cancer are often treated with radiation after surgery if they are at particularly high risk for recurrence. These risk factors should probably include abnormal ...
ascopubs.org

Beta-catenin and p53 expression in ampullary and small intestinal adenocarcinoma.

Treatment patterns and cost for colorectal cancer by line of therapy and metastasis status. Prognostic significance of presence of any mucinous component in curatively resected stage II and III ...
ascopubs.org

A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.

First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with ...
Business Wire

FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma ®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and ...